The FDA's ZYN 'Modified Risk' Claim, Explained

By PouchGuide Editorial Team · Published September 6, 2026

In June 2026, the FDA authorized Philip Morris International to market specific ZYN products with a claim that switching from cigarettes to ZYN lowers the risk of several diseases. This was widely reported as “the FDA said ZYN is safer than cigarettes” — which oversimplifies what actually happened. Here’s the specific, narrower thing the FDA actually authorized.

What the order actually says

The FDA’s Modified Risk Tobacco Product (MRTP) order permits Philip Morris to state that using ZYN instead of cigarettes puts a person at lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. That’s it — a comparative claim against cigarettes specifically, not a general safety claim.

Who the claim applies to

The authorized claim is conditioned on complete switching — the marketing language is built around people who currently smoke cigarettes and switch entirely to ZYN, not people who use both, and not people who have never smoked or used nicotine. The order does not authorize any claim aimed at non-smokers or first-time nicotine users.

Which products it covers

The order applies to the same 20 specific ZYN products (particular flavors and strengths, 3mg and 6mg) that received the original Marketing Granted Order in January 2025 — not the entire ZYN product line, and not any other nicotine pouch brand. VELO, On!, Rogue, and other competitors do not currently hold an equivalent FDA order for this specific claim.

How long it lasts

The order is time-limited — five years — and is subject to FDA postmarket surveillance. If data over that period shows the marketing is increasing nicotine use among people who don’t smoke, particularly youth, the FDA can revoke it before the five years are up.

What this doesn’t mean

It doesn’t mean the FDA has declared nicotine pouches broadly safe. It doesn’t mean every ZYN product carries the claim. It doesn’t mean any other brand can legally make the same claim without going through its own review. And it doesn’t change the underlying facts about nicotine pouches discussed on our health and safety page — nicotine is still addictive, and long-term outcome data still doesn’t exist for this product category.

Why this process exists

The FDA’s Premarket Tobacco Product Application (PMTA) and MRTP pathways exist specifically so that comparative claims like “lower risk than cigarettes” have to be backed by evidence and reviewed by a regulator, rather than left entirely to a manufacturer’s marketing department. That’s also why most other nicotine pouch brands on the market haven’t made — and legally can’t make — the same claim: they haven’t gone through the same review.